BMJ Open · 2020 · 42 citations · 19 references
Public HealthCommunity HealthPediatricsAutism Spectrum DisordersDevelopmental PediatricsEarly InterventionCare Of Premature InfantsCerebral PalsyEarly IdentificationInfant Neurological DevelopmentNeurodevelopmental AssessmentNeurodevelopmental DisordersCerebral Palsy InterventionEarly Case DetectionEarly Intervention EvaluationEarly Motor AssessmentInfant Neurodevelopmental AssessmentMovement AssessmentPediatric Movement AssessmentSocial Support Deficits
INTRODUCTION: Around 9% of India's children under six are diagnosed with neurodevelopmental disorders. Low-resource, rural communities often lack programmes for early identification and intervention. The Prechtl General Movement Assessment (GMA) is regarded as the best clinical tool to predict cerebral palsy in infants <5 months. In addition, children with developmental delay, intellectual disabilities, late detected genetic disorders or autism spectrum disorder show abnormal general movements (GMs) during infancy. General Movement Assessment in Neonates for Early Identification and Intervention, Social Support and Health Awareness (G.A.N.E.S.H.) aims to (1) provide evidence as to whether community health workers can support the identification of infants at high-risk for neurological and developmental disorders and disabilities, (2) monitor further development in those infants and (3) initiate early and targeted intervention procedures. METHODS: This 3-year observational cohort study will comprise at least 2000 infants born across four districts of Uttar Pradesh, India. Community health workers, certified for GMA, video record and assess the infants' GMs twice, that is, within 2 months after birth and at 3-5 months. In case of abnormal GMs and/or reduced MOSs, infants are further examined by a paediatrician and a neurologist. If necessary, early intervention strategies (treatment as usual) are introduced. After paediatric and neurodevelopmental assessments at 12-24 months, outcomes are categorised as normal or neurological/developmental disorders. Research objective (1): to relate the GMA to the outcome at 12-24 months. Research objective (2): to investigate the impact of predefined exposures. Research objective (3): to evaluate the interscorer agreement of GMA. ETHICS AND DISSEMINATION: G.A.N.E.S.H. received ethics approval from the Indian Government Chief Medical Officers of Varanasi and Mirzapur and from the Ramakrishna Mission Home of Service in Varanasi. GMA is a worldwide used diagnostic tool, approved by the Ethics Committee of the Medical University of Graz, Austria (27-388 ex 14/15). Apart from peer-reviewed publications, we are planning to deploy G.A.N.E.S.H. in other vulnerable settings.
19
An early marker for neurological deficits after perinatal brain lesions
H.F.R. Prechtl, Christa Einspieler, Giovanni Cioni et al. · The Lancet · 1997 · 728 citations · Full text
Medicine, Neurology, Neuroscience +14
Optimality score for the neurologic examination of the infant at 12 and 18 months of age
Leena Haataja, Eugenio Mercuri, Rivka Regev et al. · The Journal of Pediatrics · 1999 · 382 citations
Medicine, Neurology, Pediatrics +14
Christa Einspieler, Fabiana Utsch, Patrícia Brasil et al. · JAMA Network Open · 2019 · 135 citations · Full text